Over the past decades, it has become increasingly accepted that the risk of cardiovascular
(CV) morbidity and mortality is noticeably augmented in rheumatoid arthritis (RA)
patients [
[1]
]. When compared to the general population, the mere existence of said condition increases
CV death risk by up to 50% [
[2]
]. Furthermore, more than half of premature mortality in these patients is attributable
to CV disease, which remains as their leading cause of death [
2
,
3
,
4
]. Therefore, RA, by itself, is now accepted as an independent cardiovascular risk
factor, due to its inherent chronic and systemic pro-inflammatory state [
[1]
]. Nonetheless, traditional risk factors (e.g., the presence of diabetes, hypertension
or hyperlipidaemia) remain important, as they also account for a steep increase in
CV illness odds [
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.Lancet Rheumatol. 2021; 3: e58-e70https://doi.org/10.1016/S2665-9913(20)30221-6
- Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.Rheumatol. 2014; 53: 2143-2154https://doi.org/10.1093/rheumatology/keu224
- Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.Arthritis Rheumatol. 2015; 67: 1995-2003https://doi.org/10.1002/art.39195
- C-reactive protein and implications in rheumatoid arthritis and associated comorbidities.Semin Arthritis Rheum. 2021; 51: 219-229https://doi.org/10.1016/j.semarthrit.2020.11.005
- C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.Eur J Intern Med. 2022; 104C: 49-54
- ESC/EAS Guidelines for the management of dyslipidaemias.Eur Heart J. 2011; 32: 1769-1818https://doi.org/10.1093/eurheartj/ehr158
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020; 41: 111-188https://doi.org/10.1093/eurheartj/ehz455
- Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study.PLoS Med. 2020; 17e1003432https://doi.org/10.1371/journal.pmed.1003432
Article info
Publication history
Published online: August 13, 2022
Accepted:
August 10,
2022
Received:
August 3,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
